SheMed

SheMed is a female-founded health technology company based in London, UK, established in April 2024 by sisters Olivia and Chloe Ferro.

The company focuses on closing the gender gap in metabolic and personalized healthcare. Its flagship offering is the UK's first GLP-1 weight loss program designed exclusively for women, which is clinician-led and based on a blood-test-first approach tailored to female biology. SheMed provides a range of services, including the GLP-1 weight loss program using medications like Wegovy and Mounjaro, Test-to-Treat® kits for self-testing, and telemedicine services with remote medical oversight. The company emphasizes a women-centric design in its programs, ensuring safety and effectiveness by requiring clinical blood screening for eligibility. With over 100,000 women supported across the UK, SheMed aims to set a new standard of care in women's health through clinical research and personalized support.